High levels of osteoprotegerin and soluble receptor activator of nuclear factor ?B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor ? treatment-Reference-Cited by-同舟云学术

High levels of osteoprotegerin and soluble receptor activator of nuclear factor ?B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor ? treatment

Published:2002-07 Issue:7 Volume:46 Page:1744-1753
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Ziolkowska Maria,Kurowska Mariola,Radzikowska Anna,Luszczykiewicz Grazyna,Wiland Piotr,Dziewczopolski Wojciech,Filipowicz-Sosnowska Anna,Pazdur Jacek,Szechinski Jacek,Kowalczewski Jacek,Rell-Bakalarska Maria,Maslinski Wlodzimierz

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference32 articles.

1. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis

2. The role of osteoprotegerin and receptor activator of nuclear factor ?B ligand in the pathogenesis and treatment of rheumatoid arthritis

3. Osteoprotegerin ligand: a regulator of immune responses and bone physiology

4. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Variants in RANK and OPG Could Influence Disease Severity and Bone Remodeling in Patients with Early Arthritis;Life;2024-09-03

2. Ambulatory Blood Pressure in Patients With Rheumatoid Arthritis: Association With Immune Activation;The Journal of Rheumatology;2024-05-15

3. The Role of the Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Vascular Diseases: A Therapeutic Approach;Angiology;2024-01-03

4. Positive Effects of Biologics on Osteoporosis in Rheumatoid Arthritis;Journal of Rheumatic Diseases;2023-01-01

5. Targeting fibroblast-like synoviocytes in rheumatoid arthritis;Current Opinion in Pharmacology;2022-12